References
- Ghodke K, Bibi A, Rabade N, et al. CD19 negative precursor B acute lymphoblastic leukemia (B‐ALL)—immunophenotypic challenges in diagnosis and monitoring: a study of three cases. Cytometry. 2017;92:315–318.
- Tembhare PR, Ghogale S, Ghatwai N, et al. Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000. Cytometry. 2018;94:100–111.
- Tembhare PR, Ghogale S, Tauro W, et al. Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry. 2018;94:509–519.
- Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry. 2007;72:S14–S22.
- Yang W, Agrawal N, Patel J, et al. Diminished expression of CD19 in B‐cell lymphomas. Cytometry. 2005;63:28–35.
- Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.
- Masir N, Marafioti T, Jones M, et al. Loss of CD19 expression in B-cell neoplasms. Histopathology. 2006;48:239–246.
- Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117(23):6267–6276.
- Schwartz S, Rieder H, Schläger B, et al. Expression of the human homologue of rat NG2 in adult acute lymphoblastic leukemia: close association with MLL rearrangement and a CD10–/CD24–/CD65s+/CD15+ B-cell phenotype. Leukemia. 2003;17:1589.
- Korol C, Rossi J, Sanz M, et al. NK cells expressing the B cell antigen CD19: expanding the phenotypical characterization and the potential consequences from misinterpretation of this subset population. Cytometry. 2015;88:358–360.
- Soma L, Wu D, Chen X, et al. Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia. Cytometry. 2015;88:145–147.
- Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
- Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10:53.
- Israel E, Kapelushnik J, Yermiahu T, et al. Expression of CD24 on CD19–CD79a + early B-cell progenitors in human bone marrow. Cell Immunol. 2005;236:171–178.
- Dworzak MN, Fritsch G, Fröschl G, et al. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood. 1998;92:3203–3209.
- Cherian S, Miller V, McCullouch V, et al. A novel flow cytometric assay for detection of residual disease in patients with B‐lymphoblastic leukemia/lymphoma post anti‐CD19 therapy. Cytometry. 2018;94:112–120.